Navigate Up

UPMC/University of Pittsburgh Schools of the Health Sciences
For Journalists
Manager, Science Writing
Telephone: 412-647-9966

Want to Make an Appointment or Need Patient Information?

Contact UPMC at
1-800-533-UPMC (8762).

Go to Find a Doctor to search for a UPMC doctor.​



Stroke Study Expands Window of Clot Removal Treatment for Some Patients

Trial ended early after procedure demonstrates significant benefit

PITTSBURGH, Nov. 11, 2017 – A procedure to remove clots from blocked brain vessels – known as thrombectomy - may be beneficial for some stroke patients even if they come in to the emergency room beyond the 6-hour treatment window that current guidelines endorse, according to a groundbreaking study conducted by an international team of physicians and researchers led by UPMC and Emory University.
 
The results, which were first announced in May at the European Stroke Organization Conference were published today in the New England Journal of Medicine.
 
“When the irreversibly damaged brain area affected by the stroke is small, we see that clot removal can make a significant positive difference, even if performed outside the six hour window,” said Tudor Jovin, M.D., director, UPMC Stroke Institute, director UPMC Center for Endovascular Therapy and professor of neurology and neurosurgery at the University of Pittsburgh, who co-led the trial. “However, this does not diminish urgency with which patients must be rushed to the ER in the event of a stroke. The mantra ‘time is brain’ still holds true.”
 
In the study, researchers randomly assigned stroke victims who arrived at the hospital outside the six-hour time window to either thrombectomy or to standard medical therapy. To select patients for the trial, the researchers used a new paradigm, which used brain imaging and clinical criteria as opposed to just time alone.
 
“Looking at the physiological state of the brain and evaluating the extent of damage and other clinical factors may be a better way to decide if thrombectomy will benefit patients as opposed to adhering to a rigid time window,” said co-principal investigator Raul Nogueira, M.D., professor of neurology, neurosurgery and radiology at Emory University School of Medicine, and director of neuroendovascular service at Marcus Stroke & Neuroscience Center, Grady Memorial Hospital.
 
Brain imaging and clinical information (neurological deficit) was used to identify and enroll patients who had a small area of irreversibly damaged brain and a significantly larger brain tissue area that was imminently threatened by loss of blood supply, but still alive – a criterion known as clinical infarct mismatch.
 
The results showed that almost half of the patients (48.6 percent) receiving endovascular therapy had a good outcome at 90 days after treatment – defined as the patient being independent in activities of daily living – showed clinical benefit, while only 13.1 percent showed benefit in the group that received clot-busting drugs alone. There was no difference in mortality between the two groups.
 
The researchers planned to enroll a maximum of 500 patients over the course of the study period. However, a pre-planned intermediate review of the treatment effectiveness when 200 patients were enrolled led the independent Data Safety Monitoring Board overseeing the study to recommend early termination of the trial based on pre-defined criteria demonstrating that clot removal provided significant clinical benefit in the selected patients.
 
The multi-center international study known as the DAWN trial included trial locations in the United States, Spain, France, Australia and Canada. The trial was sponsored by Stryker Corporation, which manufactures the clot removal devices used in the study.

UPMC | Affiliated with the University of Pittsburgh Schools of the Health Sciences Supplemental content provided by Healthwise, Incorporated. To learn more, visit www.healthwise.org

For help in finding a doctor or health service that suits your needs, call the UPMC Referral Service at 412-647-UPMC (8762) or 1-800-533-UPMC (8762). Select option 1.

UPMC is an equal opportunity employer. UPMC policy prohibits discrimination or harassment on the basis of race, color, religion, ancestry, national origin, age, sex, genetics, sexual orientation, gender identity, marital status, familial status, disability, veteran status, or any other legally protected group status. Further, UPMC will continue to support and promote equal employment opportunity, human dignity, and racial, ethnic, and cultural diversity. This policy applies to admissions, employment, and access to and treatment in UPMC programs and activities. This commitment is made by UPMC in accordance with federal, state, and/or local laws and regulations.

Medical information made available on UPMC.com is not intended to be used as a substitute for professional medical advice, diagnosis, or treatment. You should not rely entirely on this information for your health care needs. Ask your own doctor or health care provider any specific medical questions that you have. Further, UPMC.com is not a tool to be used in the case of an emergency. If an emergency arises, you should seek appropriate emergency medical services.

UPMC
Pittsburgh, PA, USA | UPMC.com